Principal Financial Group Inc. Increases Stock Position in ADMA Biologics Inc (NASDAQ:ADMA)

Principal Financial Group Inc. lifted its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 2.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,288,121 shares of the biotechnology company's stock after acquiring an additional 29,107 shares during the quarter. Principal Financial Group Inc. owned approximately 0.54% of ADMA Biologics worth $25,556,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ADMA. Mark Sheptoff Financial Planning LLC bought a new stake in shares of ADMA Biologics during the fourth quarter worth about $35,000. Tsfg LLC acquired a new stake in ADMA Biologics during the 1st quarter worth approximately $51,000. Farther Finance Advisors LLC grew its holdings in ADMA Biologics by 1,149.1% during the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 2,505 shares during the last quarter. AlphaQuest LLC acquired a new position in ADMA Biologics in the 4th quarter valued at approximately $84,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of ADMA Biologics during the fourth quarter valued at $85,000. Institutional investors own 75.68% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on ADMA shares. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial upped their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th.

ADMA Biologics Trading Up 0.2%

ADMA traded up $0.04 during trading on Friday, reaching $18.51. 1,954,226 shares of the stock traded hands, compared to its average volume of 3,687,319. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22. The stock's 50-day moving average is $19.68 and its 200 day moving average is $18.75. ADMA Biologics Inc has a 12 month low of $10.21 and a 12 month high of $25.67. The stock has a market capitalization of $4.42 billion, a PE ratio of 21.78 and a beta of 0.43.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. During the same quarter in the previous year, the company earned $0.08 EPS. The firm's revenue for the quarter was up 40.2% on a year-over-year basis. Equities analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Activity

In other ADMA Biologics news, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the transaction, the director directly owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. This trade represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the sale, the director owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 464,621 shares of company stock worth $9,644,269. Company insiders own 3.50% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.